A Randomized, Open-label, Treat-to-target, Parallel-Controlled Phase II Clinical Study Investigating the Efficacy and Safety of SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Latest Information Update: 21 Nov 2025
At a glance
- Drugs SHR-3167 (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 18 Nov 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Feb 2026.
- 18 Nov 2025 Status changed from recruiting to active, no longer recruiting.
- 18 Nov 2025 Status changed from not yet recruiting to recruiting.